At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Jun 12, 2026 at 07:00 ET
Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, showing safety and PK/PD results consistent with prior studies. The data supports global Phase 2b trials (BROADEN2 in atopic dermatitis, BREADTH in asthma) that are ongoing with readouts expected by mid-2027 and late 2027, respectively. This is an incremental data update with no new efficacy or regulatory catalyst, a routine clinical-stage update for a $6.8B biotech.
- Phase 1 study in 24 healthy Japanese adults showed median STAT6 degradation ≥98% at both dose levels at Day 7, consistent with prior non-Japanese studies.
- KT-621 was well tolerated with a favorable safety profile across both doses.
- Parallel Phase 2b trials BROADEN2 (atopic dermatitis) and BREADTH (asthma) are ongoing; data expected by mid-2027 and late 2027, respectively.
- No new efficacy data, regulatory milestone, or financial guidance was disclosed in this press release.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access